Cardiff Oncology, Inc.
DE ˙ DB ˙ US14147L1089
€ 1,13 ↓ -0.10 (-7.78%)
2026-06-04
PREÇO DA AÇÃO
SecurityDE:XE7C / Cardiff Oncology, Inc.
InstitutionState Street Corp
Latest Disclosed Ownership693,445 shares
Ownership 1.65%
State Street Corp ownership in XE7C / Cardiff Oncology, Inc.

2022-02-09 - State Street Corp has filed an SC 13G/A form with the Securities and Exchange Commission (SEC) disclosing ownership of 693,445 shares of Cardiff Oncology, Inc. (DE:XE7C). This represents 1.65 percent ownership of the company. In their previous filing dated 2021-02-11 , State Street Corp had reported owning 2,548,772 shares, indicating a decrease of -72.79 percent.

Institutional Ownership: 13D/G Filings

This table shows a history of the 13D/G filings made by the investor and/or investor group. Note that the share values in this table are not directly comparable to any numbers shown in the 13F table (if any).

File
Date		Effective
Date		Form Prev
Shares		 Latest
Shares		 ΔShares
(Percent)		 Ownership
(Percent)		 ΔOwnership
(Percent)
2022-02-09 2022-02-09 13G/A 2,548,772 693,445 -72.79 1.65 -77.15
2021-02-11 2021-02-11 13G 2,548,772 7.22

Important Note: One of the primary uses of the 13D/G filings is to evaluate the ability of a firm to control a company (ie, the "beneficial ownership"). To that end, firms are required to report not just direct holdings in companies, but indirect holdings that they control. For investment firms, these indirect holdings can include shares in funds they manage, advisory accounts, and in the case of activist campaigns, pledged votes. Therefore, share counts listed in 13D/G filings can differ significantly than share counts listed in 13F filings.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-15 2026-03-31 13F CARDIFF ONCOLOGY COM 14147L108 1,186,947 -4,700 -0.39 1,923 -42.59 0.0001
2026-02-13 2025-12-31 13F CARDIFF ONCOLOGY COM 14147L108 1,191,647 45,288 3.95 3,349 41.80 0.0001
2025-11-14 2025-09-30 13F CARDIFF ONCOLOGY COM 14147L108 1,146,359 19,833 1.76 2,362 -33.46 0.0001
2025-08-14 2025-06-30 13F CARDIFF ONCOLOGY COM 14147L108 1,126,526 186,242 19.81 3,549 20.19 0.0001
2025-05-15 2025-03-31 13F CARDIFF ONCOLOGY COM 14147L108 940,284 91,705 10.81 2,952 -19.83 0.0001
2025-02-14 2024-12-31 13F CARDIFF ONCOLOGY COM 14147L108 848,579 15,927 1.91 3,683 65.63 0.0001
2024-11-14 2024-09-30 13F CARDIFF ONCOLOGY COM 14147L108 832,652 27,628 3.43 2,223 24.40 0.0001
2024-08-14 2024-06-30 13F CARDIFF ONCOLOGY COM 14147L108 805,024 665,079 475.24 1,787 139.22 0.0001
2024-05-15 2024-03-31 13F CARDIFF ONCOLOGY COM 14147L108 139,945 0 0.00 747 260.87 0.0000
2024-02-14 2023-12-31 13F CARDIFF ONCOLOGY COM 14147L108 139,945 0 0.00 207 6.70 0.0000
2023-11-14 2023-09-30 13F CARDIFF ONCOLOGY COM 14147L108 139,945 0 0.00 195 -5.37 0.0000
2023-08-14 2023-06-30 13F CARDIFF ONCOLOGY COM 14147L108 139,945 0 0.00 206 -10.87 0.0000
2023-05-15 2023-03-31 13F CARDIFF ONCOLOGY COM 14147L108 139,945 0 0.00 231 17.95 0.0000
2023-05-15 2022-12-31 13F/A-99 CARDIFF ONCOLOGY COM 14147L108 139,945 0 0.00 196 -9.72 0.0000
2023-05-15 2022-12-31 13F CARDIFF ONCOLOGY COM 14147L108 139,945 0 196 0.0000
2022-11-15 2022-09-30 13F CARDIFF ONCOLOGY COM 14147L108 139,945 0 0.00 216 -29.87 0.0000
2022-08-15 2022-06-30 13F CARDIFF ONCOLOGY COM 14147L108 139,945 -564,292 -80.13 308 -82.37 0.0000
2022-05-16 2022-03-31 13F CARDIFF ONCOLOGY COM 14147L108 704,237 10,792 1.56 1,747 -58.09 0.0001
2022-02-14 2021-12-31 13F CARDIFF ONCOLOGY COM 14147L108 693,445 61,889 9.80 4,168 -0.90 0.0002
2021-11-15 2021-09-30 13F CARDIFF ONCOLOGY COM 14147L108 631,556 137,065 27.72 4,206 27.92 0.0002
2021-08-16 2021-06-30 13F CARDIFF ONCOLOGY COM 14147L108 494,491 483,535 4,413.43 3,288 3,155.45 0.0002
2021-07-09 2021-03-31 13F/A-1 CARDIFF ONCOLOGY COM 14147L108 10,956 -2,537,816 -99.57 101 -99.78 0.0000
2021-05-17 2021-03-31 13F CARDIFF ONCOLOGY COM 14147L108 10,956 -2,537,816 101 0.0000
2021-02-16 2020-12-31 13F CARDIFF ONCOLOGY COM 14147L108 2,548,772 2,548,772 45,852 0.0028
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.